End-point definition and trial design to advance tuberculosis vaccine development.

ABSTRACT: Tuberculosis (TB) remains a leading infectious cause of death worldwide and the coronavirus disease 2019 pandemic has negatively impacted the global TB burden of disease indicators. If the targets of TB mortality and incidence reduction set by the international community are to be met, new more effective adult and adolescent TB vaccines are urgently needed. There are several new vaccine candidates at different stages of clinical development. Given the limited funding for vaccine development, it is crucial that trial designs are as efficient as possible. Prevention of infection (POI) approaches offer an attractive opportunity to accelerate new candidate vaccines to advance into large and expensive prevention of disease (POD) efficacy trials. However, POI approaches are limited by imperfect

SUBMITTER: Garcia-Basteiro AL 

PROVIDER: S-EPMC9488660 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature